Clinical Trials Browser

Refractory Differentiated Thyroid Gland Carcinoma

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03340506 2026-02-03

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Recruiting

110 enrolled

Recurrence

NCT04116541 2025-11-21

MegaMOST

Phase 2 Recruiting

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03975231 2025-11-10

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Phase 1 Recruiting

6 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Recruiting

270 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Recruiting

27 enrolled

CNS

Glioma

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Phase 2 Recruiting

64 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06119789 2025-03-26

MATRIX-Rare

Phase 2 Recruiting

96 enrolled

Other neoplasm

Rare Malignant Neoplasm

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2 Recruiting

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT06653517 2024-10-22

NETCAM

Phase 2 Recruiting

12 enrolled

Ameloblastoma

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

250 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05525273 2024-02-14

Swecranio

Phase 2 Recruiting

25 enrolled

CNS

Craniopharyngioma

NCT06079333 2023-10-12

NEO-ATACT

Phase 2 Recruiting

20 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

80 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

Clinical Trials

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NeoLATC

TAPUR

Dabrafenib and/or Trametinib Rollover Study

Special Drug Use-results Surveillance of Tafinlar/Mekinist

MegaMOST

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

MATRIX-Rare

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

NETCAM

EROS

FINPROVE

Swecranio

NEO-ATACT

MEMBRAINS